Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Arisaph Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Arisaph Pharmaceuticals

Alternative Names: ARI-3996; ARI-6000; Immune stimulation/vaccines - Arisaph; Tumour activated pro-drugs - Arisaph; Tumour activated pro-soft drugs - Arisaph; Ultra-smart pro-drugs - Arisaph; Ultra-smart pro-soft drugs - Arisaph

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arisaph Pharmaceuticals
  • Developer Arisaph Pharmaceuticals; Fox Chase Cancer Center
  • Class Small molecules; Vaccines
  • Mechanism of Action Fibroblast activation protein antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 29 Sep 2014 Arisaph Pharmaceuticals receives supplemental phase I and phase II STTR grant from the US National Cancer Institute for development of drug candidates using different technologies in Cancer
  • 31 Jul 2013 Arisaph Pharmaceuticals receives STTR grant from the US National Cancer Institute for development of small molecule immune modulators in Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top